



#12
gnd

1644

Dkt. 65019-DA-PCT-US/JPW/AJM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc Feldmann and Ravinder N. Maini
Serial No. : 09/754,004 Examiner: P. Gambel
Filed : January 3, 2001 Group Art Unit: 1644
For : TNF α ANTAGONISTS AND METHOTREXATE IN THE
TREATMENT OF TNF-MEDIATED DISEASE

1185 Avenue of the Americas
New York, New York 10036
September 13, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

SEP 20 2002

Sir:

TECH CENTER 1600/2900

COMMUNICATION IN RESPONSE TO
AUGUST 13, 2002 RESTRICTION REQUIREMENT

This Communication is submitted in response to the Restriction Requirement issued August 13, 2002 in connection with the above-identified application. A response to the August 13, 2002 Office Action is due September 13, 2002. Accordingly, this response is being timely filed.

In the Office Action, the Examiner required, under 35 U.S.C. §121, election of a single disclosed species from the previously elected category of autoimmune disease.

In response, applicants hereby elect with traverse the species of psoriatic arthritis for prosecution, in the event no generic claim is held allowable. Psoriatic arthritis is recited in the specification at, *inter alia*, page 7, line 11.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned

Applicants: Marc Feldmann, et al.
Serial No.: 09/754,004
Filed: January 3, 2001
Page 2

attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231.


Alan J. Morrison
Reg. No. 37,399

- 2/13/02
Date